Creating a Supportive Environment for Change Creating a supportive environment is key when adding GLP-1 and GIP supplements to your wellness routine
Changes coming to weight loss drug coverage benefits, effective January 1, 2025 Effective January 1, 2025, Independence Blue Cross (IBX) will no longer offer coverage for drugs including glucagon-like peptide-1 receptor antagonist (GLP-1) and non-glucagon-like peptide-1 receptor antagonist (non-GLP-1) indicated for and prescribed solely for weight loss in the absence of other FDA-approved clinical indications
For weight management, NICE has appraised several licensed medicines that are available through NHS pathways or regulated private clinics: Semaglutide (Wegovy) NICE Technology Appraisal TA875 recommends semaglutide as an option for managing overweight and obesity in adults with a BMI of 35 kg/m or more (or 3034.9 kg/m in certain circumstances) alongside at least one weight-related comorbidity, when used within a specialist weight management service
While the clinical evaluation of GLP-1MK-801 for weight loss awaits, efforts to broaden the scope of developing peptide-mediated targeting of ion channels are encouraged and should not be restricted to metabolic diseases
Learn what to watch for and when to contact your provider
Lukjanenko, L